Tejara Capital Ltd Raises Position in Maravai LifeSciences Holdings, Inc. $MRVI

Tejara Capital Ltd boosted its position in shares of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) by 23.1% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 3,020,209 shares of the company’s stock after buying an additional 566,768 shares during the period. Maravai LifeSciences makes up about 2.3% of Tejara Capital Ltd’s portfolio, making the stock its 5th biggest holding. Tejara Capital Ltd owned about 1.18% of Maravai LifeSciences worth $9,816,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. Monaco Asset Management SAM grew its holdings in shares of Maravai LifeSciences by 315.0% in the third quarter. Monaco Asset Management SAM now owns 3,656,337 shares of the company’s stock valued at $10,494,000 after purchasing an additional 2,775,372 shares in the last quarter. First Eagle Investment Management LLC raised its stake in Maravai LifeSciences by 299.0% during the fourth quarter. First Eagle Investment Management LLC now owns 1,799,336 shares of the company’s stock valued at $5,848,000 after purchasing an additional 1,348,405 shares in the last quarter. Royce & Associates LP lifted its position in Maravai LifeSciences by 38.0% during the third quarter. Royce & Associates LP now owns 1,761,764 shares of the company’s stock valued at $5,056,000 after purchasing an additional 484,908 shares during the last quarter. Brummer Multi Strategy AB bought a new position in Maravai LifeSciences during the fourth quarter valued at $1,488,000. Finally, Bank of America Corp DE grew its stake in shares of Maravai LifeSciences by 39.1% in the 3rd quarter. Bank of America Corp DE now owns 1,432,364 shares of the company’s stock worth $4,111,000 after buying an additional 402,719 shares in the last quarter. 50.25% of the stock is owned by hedge funds and other institutional investors.

Maravai LifeSciences Price Performance

Maravai LifeSciences stock opened at $4.29 on Friday. The firm has a 50-day moving average price of $3.44 and a 200-day moving average price of $3.43. The firm has a market capitalization of $1.10 billion, a PE ratio of -6.04 and a beta of 0.62. The company has a current ratio of 5.91, a quick ratio of 5.69 and a debt-to-equity ratio of 0.72. Maravai LifeSciences Holdings, Inc. has a 12-month low of $1.95 and a 12-month high of $4.99.

Maravai LifeSciences (NASDAQ:MRVI) last issued its quarterly earnings results on Thursday, May 7th. The company reported $0.01 EPS for the quarter, beating the consensus estimate of ($0.05) by $0.06. The company had revenue of $65.84 million for the quarter, compared to the consensus estimate of $53.00 million. Maravai LifeSciences had a negative net margin of 51.07% and a negative return on equity of 17.87%. As a group, equities research analysts forecast that Maravai LifeSciences Holdings, Inc. will post -0.26 EPS for the current year.

Analysts Set New Price Targets

Several analysts have recently issued reports on MRVI shares. Wells Fargo & Company upped their target price on shares of Maravai LifeSciences from $4.50 to $5.50 and gave the company an “overweight” rating in a research report on Friday, May 8th. Weiss Ratings cut Maravai LifeSciences from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday. Deutsche Bank Aktiengesellschaft restated a “buy” rating and set a $6.00 price objective on shares of Maravai LifeSciences in a research report on Friday, May 8th. Finally, Wall Street Zen upgraded Maravai LifeSciences from a “sell” rating to a “hold” rating in a report on Saturday, February 28th. Three analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $5.50.

Maravai LifeSciences Company Profile

Maravai LifeSciences Holdings, Inc (NASDAQ: MRVI) is a life sciences company specializing in the development and supply of critical reagents and services for the development and manufacture of biologic therapies. The company’s offerings support a range of applications in genomics, molecular diagnostics, vaccine development and next-generation sequencing. Maravai’s platforms address key challenges in nucleic acid production, protein detection, epigenetic analysis and reagent quality across the biopharmaceutical industry.

Through its product portfolio, which includes proprietary mRNA capping reagents, lipid nanoparticle delivery systems, synthetic oligonucleotides and high-precision assay kits, Maravai enables customers to accelerate research and streamline manufacturing workflows.